AstraZeneca CEO Pascal Soriot

As­traZeneca pub­lish­es in­ter­im vac­cine da­ta in Lancet, re­veals 10 hos­pi­tal­iza­tions, 1 death in piv­otal con­trol arms

Af­ter read­ing out in­ter­im re­sults in mid-No­vem­ber, As­traZeneca has been hot on the heels of Pfiz­er and Mod­er­na in get­ting its ade­n­ovirus-based vac­cine past reg­u­la­tors’ scruti­ny. Now, the drug­mak­er is turn­ing over those da­ta to the pub­lic in an ef­fort to speed up its re­view.

Among pa­tients dosed with As­traZeneca’s Covid-19 vac­cine AZD1222, there were no re­port­ed hos­pi­tal­iza­tions or se­vere cas­es af­ter 21 days com­pared with 10 pa­tients hos­pi­tal­ized and two clas­si­fied as se­vere in the con­trol arm, ac­cord­ing to in­ter­im da­ta pub­lished Tues­day in The Lancet. There was al­so one re­port­ed death in the con­trol arms of three on­go­ing stud­ies and none among those re­ceiv­ing a two-dose reg­i­men of AZD1222.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.